CRSP
CRISPR Therapeutics·NASDAQ
--
--(--)
--
--(--)
CRSP fundamentals
CRISPR Therapeutics (CRSP) released its earnings on Nov 10, 2025: revenue was 889.00K (YoY +47.67%), missed estimates; EPS was -1.17 (YoY -15.84%), beat estimates.
Revenue / YoY
889.00K
+47.67%
EPS / YoY
-1.17
-15.84%
Report date
Nov 10, 2025
EPS
Actual | -1.15 | -1.3 | -1.32 | -1.5 | -1.51 | 9.44 | -1.67 | -1.84 | -2.32 | -2.4 | -2.24 | -1.41 | -0.67 | -0.98 | -1.41 | 1.1 | -1.43 | -1.49 | -1.01 | -0.44 | -1.58 | -2.4 | -1.17 | |||||||||
Forecast | -1.0561 | -0.9507 | -1.185 | -1.2731 | -1.4727 | 3.5225 | -1.7528 | -1.7642 | -1.9391 | -2.2166 | -2.2778 | -2.2501 | -1.7412 | -2.1273 | -1.9893 | 0.0663 | -1.3607 | -1.4275 | -1.4084 | -1.2006 | -1.2436 | -1.4015 | -1.2646 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8.89% | -36.74% | -11.39% | -17.82% | -2.53% | +167.99% | +4.72% | -4.30% | -19.64% | -8.27% | +1.66% | +37.34% | +61.52% | +53.93% | +29.12% | +1559.13% | -5.09% | -4.38% | +28.29% | +63.35% | -27.05% | -71.25% | +7.48% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 157.00K | 44.00K | 148.00K | 370.00K | 539.00K | 900.70M | 824.00K | 12.90M | 940.00K | 158.00K | 94.00K | 6.00K | 100.00M | 70.00M | 0 | 201.21M | 504.00K | 517.00K | 602.00K | 35.69M | 865.00K | 892.00K | 889.00K |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02M | 18.13M | 1.92M | 2.20M | 1.40M | 900.19M | 1.23M | 2.19M | 2.80M | 2.21M | 1.85M | 7.12M | 25.85M | 1.80M | 11.89M | 140.94M | 24.34M | 12.06M | 6.54M | 8.06M | 6.29M | 6.14M | 9.12M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.81% | -99.76% | -92.31% | -83.21% | -61.44% | +0.06% | -32.73% | +490.26% | -66.43% | -92.86% | -94.91% | -99.92% | +286.85% | +3789.13% | -100.00% | +42.76% | -97.93% | -95.71% | -90.80% | +343.09% | -86.25% | -85.47% | -90.25% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for CRISPR Therapeutics year over year?What factors drove the changes in CRISPR Therapeutics's revenue and profit?Did CRISPR Therapeutics beat or miss consensus estimates last quarter?What guidance did CRISPR Therapeutics's management provide for the next earnings period?What were the key takeaways from CRISPR Therapeutics's earnings call?What is the market's earnings forecast for CRISPR Therapeutics next quarter?What were the key takeaways from CRISPR Therapeutics’s earnings call?What is CRISPR Therapeutics's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
